RANK, RANKL and osteoprotegerin in arthritic bone loss

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 2, 2005, Pages 161-170

  Bezerra, M C ^a   Carvalho, J F ^a   Prokopowitsch, A S ^a   Pereira, Rosa Maria R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arthritis; Bone loss; Erosion; Osteoprotegerin; RANK RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BONE DENSITOMETRY; BONE DENSITY; BONE DESTRUCTION; BONE EROSION; BONE MINERAL; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELL; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOLECULAR MECHANICS; NONHUMAN; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 15044344799     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005000200004     Document Type: Review

References (60)

1. Bromley M & Wooley DE (1984). Chondrocytes and osteoclasts at subchondral sites of erosions in the rheumatoid joint. Arthritis and Rheumatism, 27: 968-975.
2. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E & Goldring SR (2000). Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and Rheumatism, 43: 250-258.
3. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JMW, Ryan PF, Martin TJ & Gillespie MT (2000). Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis and Rheumatism, 43: 821-826.
4. Lacey DL, Timms E, Tan HL et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176.
5. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D & Galibert L (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 390: 175-179.
6. Wong BR, Rho J, Arron J et al. (1997). TRANCE is a novel ligand of the tumor necrosis factor family that activates c-Jun N-terminal kinase in T-cells. Journal of Biological Chemistry, 272: 25190-25194.
7. Lum L, Wong BR, Jasien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y & Blobel CP (1999). Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. Journal of Biological Chemistry, 274: 13613-13618.
8. Kong YY, Yoshida H, Sarosi I et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315-323.
9. Li J, Sarosi I & Yan XO (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences, USA, 97: 1566-1571.
10. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J & Moorehead RA (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell, 103: 41-50.
11. Hsu, H, Lacey DL, Dunstan CR, Solovyev I, Colombero A & Timms E (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences, USA, 96: 3540-3545.
12. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H & Choi Y (1999). TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Molecular Cell, 4: 1041-1049.
13. Simonet WS, Lancey DL & Dunstan CL (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89: 309-319.
14. Bucay N, Sarosi I & Dunstan CR (1998). Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development, 12: 1260-1268.
15. Boyle WJ, Simonet WS & Lacey DL (2003). Osteoclast differentiation and activation. Nature, 423: 337-342.
16. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM & Choi Y (2000). TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. Journal of Experimental Medicine, 191: 495-502.
17. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA & Noelle RJ (1993). The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T-cells. Journal of Immunology, 151: 2497-2510.
18. Josien R, Wong BR, Li HL, Steinman RM & Choi Y (1999). TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. Journal of Immunology, 162: 2562-2568.
19. Jones DH, Kong YY & Penninger JM (2002). Role of RANKL and RANK in bone loss and arthritis. Annals of the Rheumatic Diseases, 61: ii-32-ii-39.
20. Saika M, Inoue D, Kido S & Matsumoto T (2001). 17-Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142: 2205-2212.
21. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G & Pacifici R (2001). Up-regulation of TNF-producing T-cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proceedings of the National Academy of Sciences, USA, 20: 13960-13965.
22. Goldring SR & Gravallese EM (2000). Pathogenesis of bone erosions in rheumatoid arthritis. Current Opinion in Rheumatology, 12: 195-199.
23. Saidenberg-Kermanac'h N, Cohen-Solal M, Bessis N, De Vernejoul MC & Boissier MC (2004). Role of osteoprotegerin in rheumatoid inflammation. Joint Bone Spine, 71: 9-13.
24. Suda T, Takahashi N, Udagawa N, Jimi E, Gillepsie MIT & Martin TJ (1999). Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endocrine Reviews, 20: 345-357.
25. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T & Kashiwazaki S (1996). Interleukin-6 and soluble interleukin 6 receptors in the synovial fluids from rheumatoid arthritis patient are responsible for osteoclast-like cell formation. Journal of Bone and Mineral Research, 11: 88-95.
26. Weitzmann MN, Cenci S, Rifas L, Brown C & Pacifici B (2000). Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood, 96: 1873-1878.
27. Kotake S, Udagawa N, Takahashi N et al. (1999). IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. Journal of Clinical Investigation 103: 1345-1352.
28. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE & Lowik CW (2002). Interleukin 17 synergises with tumor necrosis factor alpha to induce cartilage destruction in vitro. Annals of the Rheumatic Diseases, 61: 870-876.
29. Chabaud M & Miossec P (2001). The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis and Rheumatism, 44: 1293-1303.
30. Ritchlin CT, Haas Smith SA, Li P, Hicks DG & Schwarz EM (2003). Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. Journal of Clinical Investigation, 111: 821-831.
31. Takayanagi H, Ogasawara K, Hida S et al. (2000). T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma. Nature, 408: 600-605.
32. Nakashima T, Wada T & Penninger JM (2003). RANKL and RANK as novel therapeutic targets for arthritis. Current Opinion in Rheumatology, 15: 280-287.
33. Vidal NO, Brandstrom H, Jonsson KB & Ohlsson C (1998). Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. Journal of Endocrinology, 159: 191-195.
34. Bendele A, McComb J, Gould T, MaAbee T, Semello G, Chlipala E & Guy M (1999). Animal models of arthritis: relevance to human disease. Toxicologic Pathology, 27: 134-142.
35. Kong YY, Feige U, Sarosi I et al. (1999). Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402: 304-309.
36. Campagnuolo G, Bolon B & Feige U (2002). Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis and Rheumatism, 46: 1926-1936.
37. Bolon B, Campagnuolo G & Feige U (2002). Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cellular and Molecular Life Sciences, 59: 1569-1576.
38. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L & Lotz M (2001). The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis and Rheumatism, 44: 2768-2776.
39. Benoist C & Mathis D (2000). A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Research, 2: 90-94.
40. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C & Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell, 87: 811-822.
41. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C & Gravallese EM (2001). TRANCE/RANKL knockout mice are protected from bone erosion in the K/BxN serum transfer model of arthritis. American Journal of Pathology, 159: 1689-1699.
42. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D & Benoist C (2002). Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. Journal of Experimental Medicine, 196: 77-85.
43. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D & Koelias G (1991). Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO Journal 10: 4025-4031.
44. Redlich K, Hayer S, Maier A et al. (2002). Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and Rheumatism, 46: 785-792.
45. Schett G, Redllich K, Zwerina J et al. (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis and Rheumatism, 48: 2042-2051.
46. Zwerina J, Hayer S, Tohidast-Akrad M et al. (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANK pathways in tumor necrosis factor-induced arthritis. Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis and Rheumatism, 50: 277-290.
47. Lubberts E, Oppers-Walgreen B, Pettit AR, van den Bersselaar L, Joosten LAB, Goldring SR, Gravallese EM & van den Berg WB (2002). Increase in expression of receptor activator of nuclear factor κB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis and Rheumatism, 46: 3055-3064.
48. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ & Gillespie MT (2002). Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. American Journal of Pathology, 161: 1419-1427.
49. Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S & Kitazawa S (2002). RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochemistry and Cell Biology, 117: 283-292.
50. Kotake S, Udagawa N, Hakoda M et al. (2001). Activated human T-cells directly induce osteoclastogenesis from human monocytes: possible role of T-cells in bone destruction in rheumatoid arthritis patients. Arthritis and Rheumatism, 44: 1003-1012.
51. Ziolkowska M, Kurowska A, Radzikowska A et al. (2002). High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis and Rheumatism, 46: 1744-1753.
52. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GI & Findlay DM (2001). Osteoprotegerin and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology, 40: 623-630.
53. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K & Tanaka S (2000). Involvement of receptor activator of nuclear factor κBligand /osteoclast differentiation factor in osteoclastogenesis from synoviocyte in rheumatoid arthritis. Arthritis and Rheumatism, 43: 259-269.
54. Itonaga I, Fujikawa Y, Sabokbar A, Murray DW & Athanasou NA (2000). Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. Journal of Pathology, 192: 97-104.
55. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T & Koshihara Y (1997). A new mechanism of bone destruction in rheumatoid arthritis; synovial fibroblasts induce osteoclastogenesis. Biochemical and Biophysical Research Communications, 240: 279-286.
56. Bekker PJ, Holloway D, Nakanishi A, Arrigh HM, Leese PT & Dunstan CR (2001). Osteoprotegerin (OPG) has potent and substantial anti-resorptive activity in post menopausal women. Journal of Bone and Mineral Research, 16: 348-360.
57. Fye KH (1999). New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs. Postgraduate Medicine, 106: 82-85.
58. Graninger WB & Smolen JS (2001). One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle? Current Opinion in Rheumatology, 13: 9-13.
59. Oliveri MB, Mautalen CA, Rodriguez Fuchs CA & Romanelli MC (1991). Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hospital Medical Journal 39: 45-48.
60. Lerner UH (2004). New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. CRC Critical Reviews in Oral Biology and Medicine, 15: 64-81.